Journal of Clinical & Experimental Oncology

Short Communication A SCITECHNOL JOURNAL

Analyzing Tumor-Immune Interactions between Cancer and the Immune System

Julen Zhang*

Department of Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu, China

***Corresponding Author:** Julen Zhang, Department of Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu, China; E-mail: julen_zhang@ju22.cn

Received date: 21 July, 2024, Manuscript No. JCEOG-24-148889;

Editor assigned date: 23 July, 2024, PreQC No. JCEOG-24-148889 (PQ);

Reviewed date: 06 August, 2024, QC No. JCEOG-24-148889;

Revised date: 13 August, 2024, Manuscript No. JCEOG-24-148889 (R);

Published date: 20 August, 2024, DOI: 10.4172/2324-9110.1000427

Description

Cancer remains one of the leading causes of morbidity and mortality worldwide, prompting extensive studies into its mechanisms and potential therapies. An important aspect of this studies is understanding the interactions between tumors and the immune system. The immune system plays a dual role in cancer-both as a defender against tumors and in some cases, as a facilitator of tumor growth. The immune system is a complex network of cells and proteins that defends the body against pathogens and diseases, including cancer. It consists of two main components such as innate immune system, which provides immediate, non-specific responses and the adaptive immune system, which mounts a specific response against particular threats [1].

T cells are vital for adaptive immunity. They can be further divided into helper T cells, which assist other immune cells and cytotoxic T cells, which directly kill cancer cells. B cells are responsible for producing antibodies, B cells help identify and neutralize pathogens, including tumor cells. Natural Killer (NK) cells are the part of innate immune system, NK cells can recognize and destroy cancer cells without prior sensitization. Dendritic cells these are antigen-presenting cells play a key role in connecting innate and adaptive immunity by capturing antigens and activating T cells [2,3]. While the immune system can recognize and attack cancer cells, tumors have developed various strategies to evade immune detection and destruction. Understanding these mechanisms is essential for developing effective therapies.

One of the primary mechanisms of immune evasion is the upregulation of immune checkpoint molecules on tumor cells. These molecules such as PD-L1 and CTLA-4, interact with receptors on T cells, inhibiting their activation and function [4]. By engaging these checkpoints, tumors can effectively turn off the immune response, allowing them to grow and proliferate unchecked. The Tumor Micro-Environment (TME) plays a significant role in shaping immune responses. Tumors often develop an immunosuppressive microenvironment through various means, including secretion of immunosuppressive factors. Tumors release cytokines and growth factors, such as Transforming Growth Factor-β (TGF-β) and Interleukin (IL-10), that inhibit immune cell function and promote regulatory T cell (T_{reg}) development, further lowering the immune response [5]. Tumors can attract Myeloid-Derived Suppressor Cells (MDSCs) and T_{regs} to the TME, which suppress effector T cell activity and promote tumor growth.

Tumor cells may alter or lose the expression of tumor antigens-molecules that the immune system recognizes as foreign. This can occur through mutations or loss of heterozygosity, making it difficult for T cells to identify and target these cells effectively. The interaction between tumors and the immune system is dynamic and complex, characterized by a constant battle between tumor cells and immune effectors. This relationship can be summarized in three phases such as immune recognition, immune response and immune evasion [6,7]. The first step in tumor-immune interaction is the recognition of Tumor-Associated Antigens (TAAs) by the immune system. TAAs can be derived from mutated proteins, overexpressed proteins or proteins that are normally silent in healthy tissues [8].

Dendritic cells play a central role in capturing these antigens and presenting them to T cells, initiating an immune response. Upon activation, cytotoxic T cells and NK cells seek out and destroy tumor cells expressing the recognized antigens. This response is further amplified by helper T cells, which produce cytokines that promote T cell proliferation and enhance the immune response. However, this phase can be prevented by the previously mentioned immune evasion strategies employed by tumors. As tumors evolve, they may adopt various strategies to evade the immune response [9]. The ability to escape immune detection is a characteristic of cancer progression. Tumors may also induce T cell exhaustion, a state in which T cells lose their effector functions due to prolonged antigen exposure, further weakening the immune response.

The understanding of tumor-immune interactions has paved the way for the development of innovative immunotherapies. By utilizing the immune system's potential these therapies aim to enhance anti-tumor responses and overcome immune evasion. Drugs that target immune checkpoints, such as anti-Programmed Cell Death Protein 1(PD-1) and anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) antibodies, have revolutionized cancer treatment. These agents block the inhibitory signals that tumors use to evade the immune system, allowing T cells to remain active and attack cancer cells [10]. Clinical successes have been observed in various cancers, including melanoma, lung cancer and renal cell carcinoma. Cancer vaccines aim to stimulate an immune response against specific tumor antigens. By training the immune system to recognize and attack cancer cells, these vaccines hold potential for both therapeutic and preventive applications.

Conclusion

The interactions between tumors and the immune system are complex and dynamic, involving a constant interaction of recognition, response and evasion. Understanding these interactions is essential for developing effective cancer therapies, particularly in the field of immunotherapy. As studies continues to show the complexities of tumor-immune dynamics, the potential for innovative treatments that enhance the power of the immune system grows providing hope for improved outcomes in cancer patients.

References

1. Kirschner D, Panetta JC (1998) Modeling immunotherapy of the tumor–immune interaction. J Math Biol 37:235-252.

2. Bhattacharya S, Calar K, de la Puente P (2020) Mimicking tumor hypoxia and tumor-immune interactions employing three-dimensional *in vitro* models. J Exp Clin Cancer Res 39(1):75.
3. Ru B, Wong CN, Tong Y, Zhong JY, Zhong SS, et al. (2019) TISIDB: An integrated repository portal for tumor-immune system interactions. Bioinformatics 35(20):4200-4202.
4. Lin Y, Peng L, Dong L, Liu D, Ma J, et al. Geospatial immune heterogeneity reflects the diverse tumor–immune interactions in intrahepatic cholangiocarcinoma. Cancer Discov 12(10): 2350-2371.
5. Yu JL, Jang SR (2019) A mathematical model of tumor-immune interactions with an immune checkpoint inhibitor. Appl Math Comput 362:124523.
6. Eikenberry S, Thalhauser C, Kuang Y (2009) Tumor-immune interaction, surgical treatment and cancer recurrence in a mathematical model of melanoma. PLoS Comput Biol 5(4):e1000362.
7. Donofrio A (2008) Metamodeling tumor–immune system interaction, tumor evasion and immunotherapy. Math comp model 47(6):614-637.
8. Marei HE, Althani A, Afifi N, Hasan A, Caceci T, et al. (2021) p53 signaling in cancer progression and therapy. Cancer Cell Int 21(1):703.
9. Wang Q, Shao X, Zhang Y, Zhu M, Wang FX, et al. (2023) Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med 12(10):11149-1165.
10. Kalinski P, Talmadge JE (2017) Tumor immuno-environment in cancer progression and therapy. Cancer ther 1-18.